Clinical Research
Efficacy and safety of FLAG regimen in the treatment of relapsed acute myeloid leukemia
Chai Hongyu
Published 2017-10-15
Cite as IMHGN, 2017,23(20): 3192-3195. DOI: 10.3760/cma.j.issn.1007-1245.2017.20.017
Abstract
ObjectiveTo analyze the curative effect and safety of FLAG regimen in the treatment of relapsed acute myeloid leukemia (AML).
Methods70 patients with refractory recurrent AML treated in our hospital from July 2013 to July 2016 were selected and randomly divided into study group and control group. 35 cases in the study group were treated with FLAG regimen, while 35 cases in the control group were treated with MEA regimen. After one course of treatment, the clinical efficacy and adverse reactions of the two groups were compared.
ResultsAfter 1 course of treatment, the total effective rate in the study group was 74.29%, which was higher than 51.43% in the control group, with statistically significant difference (χ2=3.92, P<0.05). There was no statistically significant difference in hematologic adverse reactions between the two groups (P>0.05); the total incidence of non-hematologic adverse reactions in the study group was 68.57%, which was significantly lower than 91.43% in the control group, with statistically significant difference (P<0.05).
ConclusionThe FLAG regimen in the treatment of refractory recurrent AML has high clinical efficacy, with low incidence of adverse reactions and high safety, worthy of clinical application and promotion.
Key words:
FLAG regimen; Acute myeloid leukemia; Clinical efficacy; Safety
Contributor Information
Chai Hongyu
Department of Hematology Oncology, Panjin Central Hospital, Panjin 124010, China
